In the rapidly evolving landscape of clinical research, understanding the nuances of regulatory expectations is crucial. This is particularly true when it comes to patient-reported outcomes (PROs), which are increasingly vital in shaping drug development strategies and regulatory decisions. For those who missed our live session, we’re thrilled to offer an on-demand webinar that delves into the FDA’s perspective on PRO data collection, ensuring that you’re not only compliant but also ahead of the curve in your research methodologies.
Expert Insights
The webinar featured a distinguished panel of experts, including Ari Gnanasakthy, Principal Scientist at RTI Health Solutions; Willie Muehlhausen, Co-CEO of Safira Clinical Research Ltd.; and Derk Arts, Founder & CEO of Castor. Their extensive experience provided attendees with a robust understanding of the current regulatory environment and practical advice on enhancing PRO data quality.
Key Takeaways
- FDA Insights on PRO Data Quality: Recent review documents from the FDA highlight the critical nature of high-quality PRO data. Our experts dissected these documents, offering insights into what the FDA is currently emphasizing in their evaluations.
- Effective PRO Collection Methods: Timing and methodology are everything. The webinar outlined optimal times for data collection and the most effective methods to ensure accuracy and compliance. This segment was particularly beneficial for clinical researchers looking to design studies that meet FDA standards.
- Best Practices for Data Quality: Minimizing errors in data collection isn’t just a regulatory requirement—it’s a necessity for meaningful clinical research. Our panel discussed strategies to enhance reliability and reduce variability in PRO data.
- ePRO Collection Challenges: Electronic methods for collecting PRO data are becoming the norm, but they come with challenges, particularly participant fatigue. Practical solutions for engaging participants and ensuring consistent data submission were a focal point.
- Importance of Tolerability Data: Tolerability data is increasingly used to differentiate drugs in the market. Understanding its role and how to effectively capture this information can provide a competitive edge.
Who Should Watch?
This webinar is designed for a wide array of professionals, from clinical researchers and trial managers to real-world evidence teams and medical affairs professionals. Anyone engaged in or interested in the nuances of PRO data collection will find valuable insights to enhance their understanding and practices.
Conclusion
Whether you’re designing a new clinical trial or looking to refine your data collection techniques, this webinar offers crucial guidance on aligning your strategies with FDA expectations. We invite you to watch the on-demand session to gain practical insights and actionable advice from leading experts in the field.
Don’t miss this opportunity to enhance your approach to patient-reported outcomes and stay ahead in the competitive field of clinical research. Watch now and start integrating these expert insights into your projects!
